Anticoagulation Therapy for Venous Thromboembolism in the Real World　― From the COMMAND VTE Registry

Anticoagulation Therapy for Venous Thromboembolism in the Real World　― From the COMMAND VTE Registry

Background:Venous thromboembolism (VTE) has a long-term risk of recurrence, which can be prevented by anticoagulation therapy.Methods and Results:The COMMAND VTE Registry is a multicenter registry enrolling 3,027 consecutive patients with acute symptomatic VTE between January 2010 and August 2014. T...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Circulation Journal 2018/04/25, Vol.82(5), pp.1262-1270
Hauptverfasser: Yamashita, Yugo, Morimoto, Takeshi, Amano, Hidewo, Takase, Toru, Hiramori, Seiichi, Kim, Kitae, Konishi, Takashi, Akao, Masaharu, Kobayashi, Yohei, Inoue, Takeshi, Oi, Maki, Izumi, Toshiaki, Takahashi, Kotaro, Tada, Tomohisa, Chen, Po-Min, Murata, Koichiro, Tsuyuki, Yoshiaki, Sakai, Hiroshi, Saga, Syunsuke, Sasa, Tomoki, Sakamoto, Jiro, Yamada, Chinatsu, Kinoshita, Minako, Togi, Kiyonori, Ikeda, Tomoyuki, Ishii, Katsuhisa, Kaneda, Kazuhisa, Mabuchi, Hiroshi, Otani, Hideo, Takabayashi, Kensuke, Takahashi, Mamoru, Shiomi, Hiroki, Makiyama, Takeru, Ono, Koh, Kimura, Takeshi, on behalf of COMMAND VTE Registry Investigators
Format: Artikel
Sprache:eng
Schlagworte:
Aged
Aged, 80 and over
Anticoagulants
Anticoagulants - administration & dosage
Anticoagulants - adverse effects
Bleeding
Female
Follow-Up Studies
Hemorrhage - chemically induced
Hemorrhage - nursing
Hemorrhage - therapy
Humans
Incidence
Male
Middle Aged
Mortality
Neoplasms - drug therapy
Neoplasms - mortality
Recurrence
Registries
Risk Factors
Thrombolytic Therapy
Time Factors
Venous thromboembolism
Venous Thromboembolism - drug therapy
Venous Thromboembolism - mortality
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Background:Venous thromboembolism (VTE) has a long-term risk of recurrence, which can be prevented by anticoagulation therapy.Methods and Results:The COMMAND VTE Registry is a multicenter registry enrolling 3,027 consecutive patients with acute symptomatic VTE between January 2010 and August 2014. The entire cohort was divided into the transient risk (n=855, 28%), unprovoked (n=1,477, 49%), and cancer groups (n=695, 23%). The rate of anticoagulation discontinuation was highest in the cancer group (transient risk: 37.3% vs. unprovoked: 21.4% vs. cancer: 43.5% at 1 year, P
ISSN:1346-9843
1347-4820
DOI:10.1253/circj.CJ-17-1128